Vendor Intelligence Report: Baohua Dongnuo Biotechnology BHD

Published 3 Jul 2026. 28-page investigative report on who is behind Baohua Dongnuo Biotechnology BHD: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 4 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Across 12 Finnrick lab tests, Baohua Dongnuo Biotechnology BHD posts 11 pass / 1 fail, for an overall pass rate of 92%. That is the strongest part of the dossier, but it is narrow: Finnrick coverage is limited to two GLP-1-related products while the captured BHD shop presents a much broader catalog.

The product signal is not evenly simple. Tirzepatide is the cleaner Finnrick purity/fill performer, while Retatrutide is still directionally usable but weaker because of the single failure. Ratings also compress under stricter Finnrick scoring, so the lab record supports “some tested lots are viable,” not a catalog-wide quality-system claim.

The identity record is the harder problem. The Finnrick-listed domain resolves to an unrelated public Chinese company, while the peptide operation appears through a different BHD storefront and a cluster of JEEP-branded sites. The report maps four concurrently active storefronts, two named sales operators, multiple Telegram and email paths, and UK-format phone numbers used by a network presenting as China-based.

Buyer guidance is product-specific rather than blanket. BHD/JEEP is more defensible for Finnrick-tested Tirzepatide and Retatrutide than for untested catalog items, but Tirzepatide carries a separate high-severity concern because the broader JEEP supply chain is tied to a public orange-cap T30 endotoxin warning. Crypto-forward payment rails, stale verification badges, copied imagery, old COA presentation, and May 2026 ghosting allegations make channel verification and lot-specific testing central before any order.

Inside the full report:

  • Per-product Finnrick pass/fail analysis, rating trajectories, and methodology-divergence charts for the two tested products
  • Domain forensics across BHD, JEEP Molly, JEEP Official, Guangzhou JEEP, and the unrelated dongbaobiotech.com record
  • Operator map covering Molly, Kelly, shared email infrastructure, Telegram handles, and UK-format phone numbers
  • Timeline of forum activity, storefront launches, stale Gray Guide verification, Reddit complaints, and the JEEP T30 endotoxin warning
  • COA and marketing-control review covering Janoshik links, copied product imagery, batch-verification claims, and vendor remedy terms
  • Transaction-risk analysis of crypto payment rails, refund/reship posture, and buyer leverage after payment

Risk assessment

  • Brand-confusion and authenticity-verification risk — high: Finnrick-listed dongbaobiotech.com resolves to unrelated Baotou Dongbao; BHD/JEEP uses at least four active peptide domains with no canonical official-channel or anti-counterfeit list.
  • Tirzepatide endotoxin-contamination risk — high: JEEP orange-cap Tirzepatide 30 mg January 2026 produced 1,350–2,306 EU/vial results; BHD evidence routes Tirzepatide buyers into the JEEP supply chain.
  • Post-payment non-delivery and crypto-remedy risk — high: Trustpilot 1.9/5 and May 2026 Reddit complaints allege ghosting after payment or “insurance”; crypto payments and vendor-controlled remedies leave buyers with little recourse.
  • COA and marketing-verification risk — medium: BHD/JEEP rely on old or unaudited Janoshik-linked COAs, Janoshik-only terms, copied Peptide Sciences imagery, and unverified batch-verification claims.
  • Untested catalog breadth risk — medium: Finnrick coverage is limited to Retatrutide and Tirzepatide (12 tests; 11 pass / 1 fail) while BHD shop shows approximately 155 products, leaving other catalog items unevaluated here.